Strata Oncology, a precision oncology platform company, today announced the close of a $26 million USD Series B funding round. New investors Pfizer Ventures, Merck Global Health Innovation Fund, Deerfield Management and Renaissance Venture Capital Fund were joined by existing investors Arboretum Ventures and Baird Capital.
Strata Oncology, a precision oncology company, today announced that Aurora Health Care, the largest healthcare system in Wisconsin, and University of Texas Health Sciences at Houston (UTHealth) have joined the Strata Precision Oncology NetworkTM (Network).
Three years after stepping down from the top job at Entergy Corp., New Orleans’ lone Fortune 500 firm, Wayne Leonard’s retirement took a bad turn. After being diagnosed with stage 4 lung cancer,Leonard was referring to Ochsner Medical Center on Jefferson Highway, where he is involved in a new initiative designed to tailor a cancer patient’s treatment to information found within their tumor’s genetic profile. That information can be used to match patients with early-phase clinical trials and enable them to participate in innovative therapies still under development.
Strata Oncology, a precision oncology company, today announced five leading healthcare systems have joined the Strata Precision Oncology Network™ (Network). Launched in February of 2017, and led by Strata Oncology, the Network is advancing precision oncology by providing advanced cancer patients routine tumor profiling and matching to a portfolio of biomarker-matched pharma-sponsored clinical trials.
Strata Oncology, Inc. (Strata), a precision oncology company, announced a collaboration with the University of California San Francisco (UCSF) to launch Stratify Prostate™ a unique initiative focused on expanding access to tumor sequencing nationwide for men with advanced prostate cancer and to dramatically accelerate enrollment into relevant targeted therapy trials.
Strata Oncology, Inc., a precision oncology company, today announced the launch of its 2.0 test, StrataNGS, a custom-designed, 90-gene targeted assay focused on actionable genetic alterations in tumor tissue, including standard of care markers and clinical trial eligibility markers.
The University of Alabama at Birmingham Comprehensive Cancer Center announces its partnership with Strata Oncology to provide patients with advanced or rare cancers with tumor profiling or sequencing at no cost. This will include primarily those with metastatic disease or whose tumors cannot be removed surgically, and will also be available to all glioblastoma and pancreatic cancer patients.
Strata Oncology, a precision oncology company, today announced an agreement with Epizyme to support patient identification and enrollment for Epizyme’s ongoing Phase 2 clinical trial of tazemetostat in patients with relapsed or refractory non-Hodgkins lymphoma (NHL).
Clovis Oncology, Inc. (NASDAQ: CLVS) and Strata Oncology, Inc. today announced an agreement to accelerate patient identification and enrollment for Clovis’ ongoing TRITON (Trial of Rucaparib in Prostate Indications) clinical trial program, which includes Phase 2 and Phase 3 clinical trials of rucaparib in metastatic castration-resistant prostate cancer, both of which are open for enrollment.
Strata Oncology today announced launch of the Strata Trial, a nationwide observational study providing no-cost tumor sequencing and clinical trial matching for 100,000 advanced cancer patients, to study the impact of tumor sequencing on clinical trial enrollment.